F 182112
Alternative Names: F-182112Latest Information Update: 25 Jan 2024
At a glance
- Originator Lunan Pharmaceutical Group
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 09 Dec 2023 Updated pharmacokinetics, efficacy and adverse events data from a phase-I trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 02 Jun 2023 Efficacy and adverse events data from a phase I trial in Multiple myeloma presented at 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 30 Jul 2021 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater, Refractory metastatic disease, In adults, In the elderly) in China (IV) in July 2021 (NCT04984434)